

## **MENDUS TO PARTICIPATE IN INVESTOR AND INDUSTRY CONFERENCES IN MARCH**

**Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will participate in the following upcoming investor and industry conferences:**

### *Dutch ATMP Summit*

Leiden, The Netherlands, March 12, 2025

Director CMC Anneke Reurs will participate and NorthX Biologics' CEO Janet Hoogstraate will present the progress of the large-scale manufacturing alliance with Mendus in a presentation titled "*How to set-up the GMP production of a cell therapy for Acute Myeloid Leukemia (AML) including automation in manufacturing, QC & release testing*" at 13.15 CET

For more information, please see [Dutch ATMP Summit](#)

### *NextGen Biomed*

London, United Kingdom, March 12 – 14, 2025

Director Immune and Disease Monitoring Hester van Zeeburg will participate as speaker and discussion panel member and hold a presentation titled "*Active immunotherapy in AML*" on March 13, 9.50 GMT

For more information, please see [NextGen Biomed 2025](#)

### *BIO Europe Spring*

Milan, Italy, March 17 - 19, 2025

CEO Erik Manting will participate for industry and investor meetings.

For more information, please see [BIO Europe Spring 2025](#)

### *Advanced Therapies Europe 2025*

London, United Kingdom, March 18 -19, 2025

CMO Jeroen Rovers and Head of Regulatory Affairs Anna Koptina will participate as speakers and discussion panel members. Anna Koptina will hold a presentation titled "*The latest developments in regulation for Advanced Therapy Medicinal Products*" on March 19, 11.40 GMT. Jeroen Rovers will hold a presentation titled "*Development of an active immunotherapy as maintenance treatment for acute myeloid leukemia*" on March 19, 13.40 GMT

For more information, please see [Advanced Therapies 2025](#)

### *Immuno-Oncology 360° Summit*

Boston, US, March 24 – 26, 2025

CEO Erik Manting will participate for investor and industry meetings during the 11th annual IO360° Summit, a conference dedicated to reporting on the latest advancements and data in Immuno-Oncology and present the lead program vididencel in a presentation titled "*Active immunotherapy to achieve durable clinical remissions in MRD+ AML*" on March 25, 16.00 ET.

For more information, please see [Immuno-Oncology 360° Summit](#)

## Press Release

06 March 2025 08:00:00 CET



### *51th annual meeting EBMT*

Florence, Italy, March 30 – April 2, 2025

CMO Jeroen Rovers will participate in the 51th annual meeting of EBMT, a non-profit medical and scientific organization connecting patients, researchers and other stakeholders to anticipate the future of cellular and stem cell-based therapies.

For more information, please see [51th annual meeting EBMT](#)

### **For more information, please contact:**

Erik Manting

Chief Executive Officer

E-mail: [ir@mendus.com](mailto:ir@mendus.com)

### **About Mendus AB (publ)**

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life.

We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <https://www.mendus.com/>